Answers are grounded in this paper and cite their sources.
Given the broad therapeutic benefits of molecular hydrogen, gastrointestinal delivery of this gasotransmitter is attractive for treating localized inflammatory diseases, yet conventional H2-releasing formulations suffer from limited solubility and poor tunability. Here, we develop gas-releasing frameworks (GRFs) for effective H2 delivery to the gastrointestinal tract. GRFs provide 20,000-fold higher hydrogen storage than hydrogen-rich water (HRW), prevent burst leakage in acidic gastric fluid, and enable sustained, inflammation-targeted H2 release in the intestine. After H2 release, the dynamic framework sequesters toxic boron within a reconstituted Si-O-B architecture, promoting fecal rather than systemic boron accumulation and improving long-term biosafety. Consequently, GRFs outperform HRW in mitigating oxidative damage and inflammation in dextran sulfate sodium-induced colitis, radiation-induced colitis, and high-fat diet-induced non-alcoholic fatty liver disease. Collectively, these gas-releasing frameworks provide a feasible, safe, and translatable strategy for gastrointestinal delivery of therapeutic gases and treatment of inflammatory disorders. Hydrogen therapy is limited by efficient storage and controlled release. Here, the authors show that gas-releasing frameworks enable high-capacity, sustained intestinal H2 delivery for management of multiple inflammatory disorders.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: